Dov Goldstein, MD, MBA
Chief Financial Officer
Dov joins BioAge from Indapta Therapeutics, where he served as chief financial and business officer from 2020 to 2021 and was responsible for the company’s growth strategies as well as operational finance and business development. Previously, Dov was CEO at RIGImmune from 2018 to 2020, CFO of Schrödinger from 2017 to 2018, and a partner at Aisling Capital from 2006 to 2017. From 2014 to 2015, he served as the CFO of Loxo Oncology, which was later acquired by Lilly for $8 billion. From 2000 to 2005, Dov served as CFO of Vicuron Pharmaceuticals (acquired by Pfizer in 2005 for $1.9 billion), where he raised over $250 million in equity financing and played major roles in the company’s partnership transactions. Dov currently serves on the board of directors of Gain Therapeutics, Neubase Therapeutics, and Coya Therapeutics, and previously held seats on the boards of, ADMA Biologics, Cempra Pharmaceuticals, Durata Therapeutics, Esperion Therapeutics, and Loxo Oncology. Dov has an MD from Yale School of Medicine, an MBA from Columbia Business School, and a BS in Biological Sciences from Stanford University.